AB Science annonce l’obtention d’un brevet sur le masitinib au Japon pour le traitement de la sclérose latérale amyotrophique, renforçant ainsi la position de la société en matière de propriété intellectuelle jusqu’en 2037
18 avr. 2023 12h55 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE L'OBTENTION D'UN BREVET SUR LE MASITINIB AU JAPON POUR LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE, RENFORÇANT AINSI LA POSITION DE LA SOCIÉTÉ EN...
Researchers Discover a New Embryonic Brain Circuit
13 avr. 2023 10h54 HE
|
Institute of Molecular and Clinical Ophthalmology Basel (IOB)
EMBARGOED UNTIL 17-APR-2023 11:00 ET The findings may provide new insights into circuit abnormalities in autism. ...
AB Science : Les résultats du masitinib dans la SLA seront présentés à l’AAN 2023, et incluent l’analyse de la survie à long terme et une nouvelle analyse concernant la population de patients sans perte fonctionnelle à l'inclusion
12 avr. 2023 12h23 HE
|
AB Science
COMMUNIQUE DE PRESSE LES RÉSULTATS DU MASITINIB DANS LA SLA ONT ÉTÉ SÉLECTIONNÉS POUR UNE PRÉSENTATION SCIENTIFIQUE À LA RÉUNION ANNUELLE 2023 DE L'AMERICAN ACADEMY OF NEUROLOGY, ET INCLUENT...
AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline
12 avr. 2023 12h23 HE
|
AB Science
PRESS RELEASE RESULTS OF MASITINIB IN ALS SELECTED FOR A SCIENTIFIC PLATFORM PRESENTATION AT THE AMERICAN ACADEMY OF NEUROLOGY 2023 ANNUAL MEETING, INCLUDING LONG-TERM SURVIVAL...
Global Personalized Medicine Market Is Expected to Reach $869.5 Billion by 2031: Says AMR
05 avr. 2023 10h30 HE
|
Allied Market Research
Portland, OR, April 05, 2023 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Personalized Medicine Market was valued at $300.0 billion in 2021, and is...
AB Science annonce avoir répondu aux questions au D120 de la procédure EMA de demande d’autorisation conditionnelle du masitinib dans la sclérose latérale amyotrophique et précise le nouveau calendrier de réponse à Santé Canada
04 avr. 2023 12h10 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE AVOIR REPONDU AUX QUESTIONS AU D120 DE LA PROCEDURE EMA DE DEMANDE D’AUTORISATION CONDITIONNELLE DU MASITINIB DANS LA SCLEROSE LATERALE AMYOTROPHIQUE ET...
AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for responding to Health Canada
04 avr. 2023 12h10 HE
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THAT IT HAS SUBMITTED ITS RESPONSE TO THE DAY 120 QUESTIONS IN THE EMA REGULATORY REVIEW OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AND CLARIFIES THE NEW...
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
22 mars 2023 20h31 HE
|
Biogen Inc.
CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System...
Global Mobile Tomography Market Anticipated to Garner $1,371.1 Million, Growing with 8.2% CAGR in the 2022–2031 Timeframe [240-Pages] | Depicted by Research Dive
21 mars 2023 09h05 HE
|
Research Dive
New York, USA, March 21, 2023 (GLOBE NEWSWIRE) -- Research Dive has published a new report on the global mobile tomography market. According to the report, the global market is projected to surpass...
IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.
20 mars 2023 08h45 HE
|
IGC Pharma, Inc.
POTOMAC, Md., March 20, 2023 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it will begin operating under the new name IGC...